Solid Biosciences Touts Encouraging Results For Duchenne Gene Therapy, FDA Talks Planned

Benzinga_recent_news03:14

Solid Biosciences Inc. (NASDAQ:SLDB) shares are tumbling on Wednesday following a recent update regarding the company’s clinical trial for SGT-003, an investigational gene therapy. The company on ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2618197852?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/11/Gene-therapy.jpeg?optimize=medium&dpr=2&auto=webp&width=240","is_english":true,"pubTime":"2026-03-12 03:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618197852","market":"us","top_or_hot":-1,"title":"Solid Biosciences Touts Encouraging Results For Duchenne Gene Therapy, FDA Talks Planned","media":"Benzinga_recent_news","content":"<div>\n<p>Solid Biosciences Inc. (NASDAQ:SLDB) shares are tumbling on Wednesday following a recent update regarding the company’s clinical trial for SGT-003, an investigational gene therapy.\nThe company on ...</p>\n\n<a href=\"https://www.benzinga.com/markets/biotech/26/03/51197197/solid-biosciences-touts-encouraging-results-for-duchenne-gene-therapy-fda-talks-planned\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Solid Biosciences Touts Encouraging Results For Duchenne Gene Therapy, FDA Talks Planned</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSolid Biosciences Touts Encouraging Results For Duchenne Gene Therapy, FDA Talks Planned\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-12 03:14 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/markets/biotech/26/03/51197197/solid-biosciences-touts-encouraging-results-for-duchenne-gene-therapy-fda-talks-planned><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Solid Biosciences Inc. (NASDAQ:SLDB) shares are tumbling on Wednesday following a recent update regarding the company’s clinical trial for SGT-003, an investigational gene therapy.\nThe company on ...</p>\n\n<a href=\"https://www.benzinga.com/markets/biotech/26/03/51197197/solid-biosciences-touts-encouraging-results-for-duchenne-gene-therapy-fda-talks-planned\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://www.benzinga.com/markets/biotech/26/03/51197197/solid-biosciences-touts-encouraging-results-for-duchenne-gene-therapy-fda-talks-planned","article_id":"2618197852","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/11/Gene-therapy.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/biotech/26/03/51197197/solid-biosciences-touts-encouraging-results-for-duchenne-gene-therapy-fda-talks-planned","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2618197852","pubTimestamp":1773256440,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Solid Biosciences stock fell 8% after new SGT-003 Duchenne trial data. Investors remain cautious despite promising results and FDA plans.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4585":"ETF&股票定投概念","SLDB":"Solid Biosciences","SMA":"Smartstop Self Storage REIT Inc","BK4139":"生物科技","BK4217":"自存仓储房地产信托","LABU":"三倍做多标普生物-Direxion"},"translate_title":"Solid Biosciences宣传杜兴基因疗法取得令人鼓舞的结果，FDA计划进行会谈","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SMA":1,"SLDB":1.5,"LABU":1.5},"content_text":"Solid Biosciences Inc. (NASDAQ:SLDB) shares are tumbling on Wednesday following a recent update regarding the company’s clinical trial for SGT-003, an investigational gene therapy.\nThe company on Wednesday reported interim data from its Phase 1/2 INSPIRE DUCHENNE clinical trial, where 40 participants have been dosed with SGT-003.\nThe new data included additional muscle biopsy, serum biomarker, cardiac function, and safety analyses.\nThe trial has shown promising results, including robust microdystrophin expression and improvements in muscle integrity, which are critical for patients suffering from Duchenne muscular dystrophy.\nAdditionally, SGT-003 has demonstrated an encouraging safety profile and has been well-tolerated among participants.\nThe company plans to meet with the FDA in the first half of 2026 to discuss a potential accelerated approval pathway for SGT-003, which could significantly impact its market position.\nThe company expects to provide an update in mid-2026.\nIn February, Solid Biosciences announced a regulatory update from its recent Type C meeting with the U.S. Food and Drug Administration (FDA) for SGT-003.\nThe stock is currently trading 18.9% above its 20-day simple moving average (SMA) and 31.6% above its 100-day SMA, indicating a strong short-term trend.\nOver the past 12 months, shares have increased 33.87%, and they are currently positioned closer to their 52-week highs than lows.\nThe RSI is at 70.01, which is considered overbought territory, suggesting that the stock may be due for a correction. Meanwhile, the MACD is at 0.2936, above its signal line at 0.0927, indicating bullish momentum.\nThe combination of overbought RSI and bullish MACD suggests bearish momentum, indicating potential volatility ahead.\nAnalyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $14.12. Recent analyst moves include:\nBelow is the Benzinga Edge scorecard for Solid Biosciences, highlighting its strengths and weaknesses compared to the broader market:\nThe Verdict: Solid Biosciences’ Benzinga Edge signal reveals a strong momentum score, indicating positive market sentiment. However, the overbought RSI suggests caution for short-term traders as the stock may be due for a pullback.\nSLDB Price Action: Solid Biosciences shares were down 9.72% at $7.38 at the time of publication on Wednesday, according to Benzinga Pro data.\nImage via Shutterstock\nTo add Benzinga News as your preferred source on Google, click here.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory,dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2618197852","isCrawlerRequest":true}